BioSpace News Archive

Spero Therapeutics, Inc. announced that on June 30, 2020, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 40,000 shares of its common stock to five new employees under the Spero Therapeutics, Inc.

Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA®, an infusion treatment for amyotrophic lateral sclerosis, is now listed on the Saskatchewan Formulary.

Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, today provided a guidance update on the timing of certain expected key milestones for 2020.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN) (OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), is pleased to announce, further to its press release dated June 19th, 2020,

GCAR, Eisai and UPMC, on Behalf of REMAP-CAP Investigator Network, Announce Eritoran’s Inclusion in REMAP-COVID, An Adaptive Clinical Trial to Test Interventions for Patients With Moderate and Severe COVID Infection

Innovative Medicines Canada released the following statement today in response to the Federal Court of Canada’s decision on its judicial review application regarding the Patented Medicine Prices Review Board amendments to the Patented Medicines Regulations:

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”), today announced the advancement to the final dose level in its ongoing clinical trial of CRV431, a Phase 1b multiple ascending dose (“MAD”) study.

Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers announces that after careful consideration the Company has decided to postpone its management information circular and the Annual General Meeting (“AGM”).

ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq:ANIP) today announced the launch of Mexiletine Hydrochloride Capsules USP, 150mg, 200mg and 250mg. The current annual U.S. market for this product is approximately $16 million , according to IQVIA/IMS Health. Patrick Walsh , ANI’s Interim President and CEO, stated, “This is our sixth ge

GRDG Sciences, LLC (“GRDG”) announced today that their 3F Biofragrance, developed in strategic partnership with Chemia Corporation (“Chemia”), was successful at killing SARS-CoV-2, the virus causing the COVID-19 pandemic. 3F Biofragrance was designed to satisfy the goals and principles of Project Bioshield and the Open Air